360° Coverage : Paid Rheumatoid Arthritis (RA) Clinical Trial Now Enrolling at...

1 Updates

Paid Rheumatoid Arthritis (RA) Clinical Trial Now Enrolling at Achieve Clinical Research in Birmingham, Alabama; Accepting M/F Patients with RA Age 18 - 75

Oct 16 2013, 4:18pm CDT | by PR.com

Achieve is conducting a study to evaluate the safety and efficacy of a new drug versus rituximab in patients with moderately to severely active rheumatoid arthritis (RA).

Birmingham, AL, October 16, 2013 --(PR.com)-- *To see if you qualify for this RA Clinical Trial in Alabama, visit Achieve Clinical Research on the web (http://www.achieveclinical.com/). There is...

Filed under: news

YouTube Videos

 
 
 

49 weeks ago

Paid Rheumatoid Arthritis (RA) Clinical Trial Now Enrolling at Achieve Clinical Research in Birmingham, Alabama; Accepting M/F Patients with RA Age 18 - 75

Oct 16 2013, 4:18pm CDT | by PR.com

Achieve is conducting a study to evaluate the safety and efficacy of a new drug versus rituximab in patients with moderately to severely active rheumatoid arthritis (RA).

Birmingham, AL, October 16, 2013 --(PR.com)-- *To see if you qualify for this RA Clinical Trial in Alabama, visit Achieve Clinical Research on the web (http://www.achieveclinical.com/). There is no cost to participate, no insurance is required, and you may receive compensation for time and travel.

Study Design

This is a 48-week, double-blind, multiple dose, parallel group trial to compare the safety, efficacy, immunogenicity and tolerability of an experimental drug to Rituxan and MabThera in patients with moderately to severely active RA. Patients will be enrolled across 250 clinical sites, in 26 countries.

Part I (48-week duration) will include 150 patients, which is considered sufficient for pharmacokinetics (PK) testing. Part II consists of a 48-week comparative safety/efficacy analyses with an additional 150 patients.

Background & Rationale

Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease characterized by synovial inflammation in the joints and consequently, progressive joint destruction. Depending on the severity of the disease, systemic manifestations may occur including lung disease, rheumatoid nodules and cardiovascular system effects. Without effective RA treatment, this disease may lead to severe functional disabilities, and therefore a considerable reduction in quality of life for the patient. The prevalence of RA varies with factors such as gender, race and smoking status and is approximately 0.5-1%.

B lymphocytes (B cells) are thought to play a crucial role in the pathogenesis of RA. They are also the primary source of rheumatoid factors (RFs) and anti-cyclic citrullinated peptide (anti-CCP) antibodies which contribute to the formation of immune complexes and complement activation in inflamed joints. Thus, B cell targeted therapy could play an important role in RA through a reduction in the B cell count as well as a reduction in B cell-mediated downstream effects on other cell types involved in the inflammatory response.

Primary Objectives

The primary objectives of this trial are:

To show PK similarity of this new drug to MabThera and Rituxan and of Rituxan to MabThera (three-way PK similarity).
To establish statistical equivalence of efficacy of this new drug and Rituxan/MabThera, in patients with moderately to severely active RA

Inclusion Criteria

Male or female participants, between 18 and 80 years of age, who have a diagnosis of moderately to severely active RA for at least 6 months

Patients must have had an inadequate response or intolerance to conventional DMARD therapy including at least one TNF inhibitor.

Positive for RF and/or anti-CCP antibodies.

Current treatment for RA on an outpatient basis:

-- Must be currently receiving and tolerating oral or parenteral MTX therapy at a dose of 15-25 mg per week (dose may be as low as 10 mg per week if the patient is unable to tolerate a higher dose) for at least 12 weeks immediately prior to Day 1.

-- Patients must be willing to receive oral folic acid (at least 5 mg/week or as per local practice) or equivalent during the entire study (mandatory co-medication for MTX treatment).

-- Biologic agents and DMARDs (other than MTX) must be withdrawn at least 2 weeks prior to Day 1.

-- Leflunomide must be withdrawn at least 8 weeks prior to Day 1 or a minimum of 2 weeks prior to Day 1 if after 11 days of standard cholestyramine washout.

-- If receiving current treatment with oral corticosteroids (other than intra-articular or parenteral), the dose must not exceed 10 mg/day prednisolone or equivalent. During the 4 weeks prior to Baseline (Day 1) the dose must remain stable.

-- Intra-articular and parenteral corticosteroids are not permitted within 6 weeks prior to Baseline Day 1 or throughout the trial, with the exception of IV administration of 100 mg methylprednisolone 30 to 60 minutes prior to each infusion
as this is part of the trial procedures.

-- Any concomitant non-steroidal anti-inflammatory drugs (NSAIDs) must be stable for at least 2 weeks prior to Day 1.

-- Patients may be taking oral hydroxychloroquine provided that the dose is not greater than 400 mg/day or chloroquine provided that the dose is not greater than 250 mg/day.

*Achieve Clinical Research conducts Phase II-IV Clinical Trials in Alabama. For more information about participating in an RA Clinical Study, please visit our website or contact us directly at (205) 380-6434.

Contact Information:
Achieve Clinical Research
Lashondra Cade
(205) 380-6434 320
Contact via Email
www.achieveclinical.com

Read the full story here: http://www.pr.com/press-release/520216

Press Release Distributed by PR.com

Source: PR.com

 

Don't miss ...

 

blog comments powered by Disqus

Latest stories

Apple benefited from illegal tax agreements in Ireland: EU
Brussels, Oct 1 (IANS) European Union (EU) regulators Tuesday announced that Apple Inc. enjoyed state aid from Ireland for many years via illegal tax agreements.
 
 
Serious about taking forward civil nuclear deal: Modi
Washington, Sep 30 (IANS) Prime Minister Narendra Modi said Tuesday that he has conveyed to US President Barack Obama that India is "serious about taking forward" the civil nuclear deal with the US and resolving issues.
 
 
Sought access for Indian companies to American markets: Modi
Washington, Sep 30 (IANS) Prime Minister Narendra Modi said Tuesday that he has urged US President Barack Obama to take steps that would help Indian service companies get access to the US economy.
 
 
Unique 'signature' found in ageing brain
London, Sep 30 (IANS) In a discovery that may lead to treatments that can slow or reverse cognitive decline in the elderly, researchers have found evidence of a unique "signature" in the ageing brain.
 
 
 

Latest from the Network

Apple benefited from illegal tax agreements in Ireland: EU
Brussels, Oct 1 (IANS) European Union (EU) regulators Tuesday announced that Apple Inc. enjoyed state aid from Ireland for many years via illegal tax agreements. The European Commission expressed concern over tax...
Read more on Business Balla
 
Liam Hemsworth's family thought he was posessed
Liam Hemsworth's family thought he was possessed by demons when he was a child. The Australian actor, 24, admits he and his older brother Chris Hemsworth, 31, were very naughty when they were growing up, as their...
Read more on Celebrity Balla
 
Anne Hathaway only settled into married life last year
Anne Hathaway's first year of married life was ''insane.'' The 'Les Miserables' actress, who tied the knot with jewelry designer Adam Shulman in Big Sur, California in September 2012, admits she only started to settle...
Read more on Celebrity Balla
 
George Clooney donating profits from wedding photos to his own charity
George Clooney is donating most of the profits from his wedding photographs to his own charity. The 53-year-old actor, who tied in the knot with British human rights lawyer Amal Alamuddin, 36, in Venice, Italy during a...
Read more on Celebrity Balla
 
Justin Bieber meets Kendall Jenner in Paris
Justin Bieber enjoyed a boozy lunch with Kendall Jenner today (09.30.14). The 'Baby' hitmaker, who is currently in Paris with his on-again, off-again girlfriend Selena Gomez, was spotted sipping champagne with the 18-...
Read more on Celebrity Balla
 
The displaced from eastern Ukraine continue to flow
Odessa (Ukraine), Oct 1 (IANS/EFE) Despite a recent ceasefire, the people displaced by the separatist conflict in Donetsk and Lugansk in eastern Ukraine continue to flock to different areas of the country, including...
Read more on Politics Balla
 
Alicia Keys may deliver baby on New Year's Eve
Los Angeles, Oct 1 (IANS) Singer Alicia Keys has disclosed that her due date for the delivery of her second child is on New Year's Eve this time. She finds it "cute". She is likely to deliver her baby Dec 31, 2014....
Read more on Celebrity Balla
 
IS forces closing in on Syrian-Kurdish town
Beirut, Oct 1 (IANS/EFE) The Islamic State Sunni radical group advanced Tuesday on Kobani, the Syrian-Kurdish town on the Turkish border, and have come within two or three kilometres of the strategic town, the Syrian...
Read more on Politics Balla
 
20 killed in Algeria bus accident
Algiers, Oct 1 (IANS) At least 20 passengers were killed Tuesday in a road accident in Algeria, media reports said. The accident occurred in the southern city of Laghouat when two buses collided, leaving more than 20...
Read more on Politics Balla
 
New confidence, new excitement in India-US ties: Modi (Roundup)
Washington, Oct 1 (IANS) Saying there is "new confidence, new excitement" in the India-US relationship, Indian Prime Minister Narendra Modi Tuesday assured the US of India's commitment to take their stalled landmark...
Read more on Politics Balla